HKU Scholars Hub: Search

Search

Results 1-25 of 53 (Search time: 0.014 seconds).

previous
1
2
3
next

	Title	Author(s)	Issue Date
	Pathway analysis using random forests classification and regression Journal:Bioinformatics	Pang, H Lin, A Holford, M Enerson, BE Lu, B Lawton, MP Floyd, E Zhao, H	2006
	Building pathway clusters from Random Forests classification using class votes Journal:BMC Bioinformatics	Pang, H Zhao, H	2008
	Shrinkage-based diagonal discriminant analysis and its applications in high-dimensional data Journal:Biometrics	Pang, H Tong, T Zhao, H	2009
	A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602) Journal:Journal of Thoracic Oncology	Miller, AA Pang, H Hodgson, L Ramnath, N Otterson, GA Kelley, MJ Kratzke, RA Vokes, EE	2010
	Pathway analysis using random forests with bivariate node-split for survival outcomes. Journal:Bioinformatics (Oxford, England)	Pang, H Datta, D Zhao, H	2010
	A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer Journal:Anticancer Research	Wong, NS Fernando, NH Nixon, AB Cushman, S Aklilu, M Bendell, JC Morse, MA Blobe, GC Ashton, J Pang, H Hurwitz, HI	2011
	A phase II study of sorafenib in malignant mesothelioma: Results of Cancer and Leukemia Group B 30307 Journal:Journal of Thoracic Oncology	Dubey, S Jänne, PA Krug, L Pang, H Wang, X Heinze, R Watt, C Crawford, J Kratzke, R Vokes, E Kindler, HL	2010
	Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304) Journal:Journal of Thoracic Oncology	Otterson, GA Hodgson, L Pang, H Vokes, EE	2010
	Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study Journal:Journal of Clinical Oncology	Ready, NE Dudek, AZ Pang, HH Hodgson, LD Graziano, SL Green, MR Vokes, EE	2011
	A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer Journal:Oncologist	Altomare, I Bendell, JC Bullock, KE Uronis, HE Morse, MA Hsu, SD Zafar, SY Blobe, GC Pang, H Honeycutt, W Sutton, L Hurwitz, HI	2011
	A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer Journal:Clinical Colorectal Cancer	Wong, NS Fernando, NH Bendell, JC Morse, MA Blobe, GC Honeycutt, W Pang, H Hurwitz, HI	2011
	Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and leukemia group B 30601): A brief report Journal:Journal of Thoracic Oncology	Dudek, AZ Pang, H Kratzke, RA Otterson, GA Hodgson, L Vokes, EE Kindler, HL	2012
	Pathway-based identification of SNPs predictive of survival Journal:European Journal of Human Genetics	Pang, H Hauser, M Minvielle, S	2011
	Statistical properties on semiparametric regression for evaluating pathway effects Journal:Journal of Statistical Planning and Inference	Kim, I Pang, H Zhao, H	2013
	Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206 Journal:Journal of Thoracic Oncology	Kelley, MJ Bogart, JA Hodgson, LD Ansari, RH Atkins, JN Pang, H Green, MR Vokes, EE	2013
	IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients Journal:Journal of Hepatology	Garrett, ME Abdelmalek, MF Ashley-Koch, A Hauser, MA Moylan, CA Pang, H Diehl, AM Tillmann, HL	2013
	Determinants of a subject's decision to participate in clinical anesthesia research Journal:Anesthesia and Analgesia	Balajonda, N Bisanar, TL Mathew, JP Pang, H Voils, CI	2013
	Gene selection using iterative feature elimination random forests for survival outcomes Journal:IEEE/ACM Transactions on Computational Biology and Bioinformatics	Pang, H George, SL Hui, K Tong, T	2012
	NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease Journal:Gut	Syn, W-K Agboola, KM Swiderska, M Michelotti, GA Liaskou, E Pang, H Xie, G Philips, G Chan, IS Karaca, GF Pereira, TDA Chen, Y Mi, Z Kuo, PC Choi, SS Guy, CD Abdelmalek, MF Diehl, AM	2012
	Bayesian semiparametric regression models for evaluating pathway effects on continuous and binary clinical outcomes Journal:Statistics in Medicine	Kim, I Pang, H Zhao, H	2012
	A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas Journal:Oncologist	Uronis, HE Bendell, JC Altomare, I Blobe, GC David Hsu, S Morse, MA Pang, H Yousuf Zafar, S Conkling, P Favaro, J Arrowood, CC Cushman, SM Meadows, KL Brady, JC Nixon, AB Hurwitz, HI	2013
	Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes Journal:Genetic Epidemiology	Pang, H Jung, S-H	2013
	Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70Gy daily radiotherapy: CALGB 30904 Journal:Lung Cancer	Salama, JK Pang, H Bogart, JA Blackstock, AW Urbanic, JJ Hodgson, L Crawford, J Vokes, EE	2013
	Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: A re-analysis of meta-analyses of individual patients' data Journal:The Lancet Oncology	Mauguen, A Pignon, J-P Burdett, S Domerg, C Fisher, D Paulus, R Mandrekar, SJ Belani, CP Shepherd, FA Eisen, T Pang, H Collette, L Sause, WT Dahlberg, SE Crawford, J O'Brien, M Schild, SE Parmar, M Tierney, JF Pechoux, CL Michiels, S	2013
	Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012 Journal:Journal of Clinical Oncology	Pang, HMH Wang, X Stinchcombe, TE Wong, ML Cheng, KMP Ganti, AK Sargent, DJ Zhang, Y Hu, C Mandrekar, SJ Redman, MW Manola, JB Schilsky, RL Cohen, HJ Bradley, JD Adjei, AA Gandara, D Ramalingam, SS Vokes, EE	2016